arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Lipocine Inc.

LPCN
$1.52 ▲ +0.06 (+4.11%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lipocine Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.3M
Dividend Yield —
Revenue Growth -82.3%
Op. Margin None
ROIC -71.6% ↘
FCF / Share $-1.79 ↘
Trailing P/E —
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.98M
↓ -82.3% —
Net Income Profit after all expenses
$-9.63M
↓ -115371.9% —
Operating Margin Operating profit as % of sales
-10.3%
↓ -152.9% —
FCF / Share Free cash flow per share
$-1.79
↓ -629.3% —
Long-Term Debt Long-term obligations
$1.67M
↓ -26.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↓
13
Cash Quality ↓
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 62 quarters